Home Cart Sign in  
Chemical Structure| 150651-39-1 Chemical Structure| 150651-39-1

Structure of iFSP1
CAS No.: 150651-39-1

Chemical Structure| 150651-39-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

iFSP1 is a FSP1 (Ferroptosis suppressor protein 1) inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of iFSP1

CAS No. :150651-39-1
Formula : C20H13N5
M.W : 323.35
SMILES Code : N#CC1=C(N)N2C(C(C#N)=C1C3=CC=C(C)C=C3)=NC4=CC=CC=C42
MDL No. :MFCD01572665
InChI Key :FNESYDFRCQEEKA-UHFFFAOYSA-N
Pubchem ID :699043

Safety of iFSP1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P233-P260-P261-P264-P270-P271-P280-P301+P312-P302+P352-P304-P304+P340-P305+P351+P338-P312-P321-P330-P332+P313-P337+P313-P340-P362-P403-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OVCAR3 cells 10 μM 48 hours Evaluate the inhibitory effect of iFSP1 combined with olaparib on ovarian cancer cell proliferation PMC11043371
SKOV3 cells 10 μM 48 hours Evaluate the inhibitory effect of iFSP1 combined with olaparib on ovarian cancer cell proliferation PMC11043371
A2780 cells 10 μM 48 hours Evaluate the inhibitory effect of iFSP1 combined with olaparib on ovarian cancer cell proliferation PMC11043371
HO-8910 cells 10 μM 48 hours Evaluate the inhibitory effect of iFSP1 combined with olaparib on ovarian cancer cell proliferation PMC11043371
4T1 cells 10 μM (TBT-CQi), 20 μM (iFSP1) 4 hours Evaluate the uptake of TiF NPs by 4T1 cells, ROS generation, LPO levels, NADH and CoQ10 levels. Results showed that TiF NPs effectively accumulated on the cell membrane, generated ROS, increased LPO levels, decreased NADH and CoQ10 levels, and induced apoptosis and ferroptosis. PMC11732120
Primary mouse hepatocytes (P-Hepa) 10 μM 24 hours IFSP1 induced ferroptosis in male hepatocytes, while female hepatocytes exhibited lower sensitivity to iFSP1-induced ferroptosis. PMC10519854
HepG2 cells 10 μM 24 hours IFSP1 induced ferroptosis in HepG2 cells, leading to significant increases in mitochondrial Fe2+ content and mitochondrial ROS (mtROS) production. PMC10519854
MHCC97L 1.5, 3, 10 μM 24 hours IFSP1 significantly suppressed HCC cell proliferation and dose-dependently increased intracellular lipid peroxidation and cell death PMC10230009
Rat nucleus pulposus cells 5 μM To evaluate the effect of iFSP1 on TNFα-mediated inflammatory pathway, results showed that iFSP1 significantly inhibited TNF signaling pathway. PMC11565395
Rat nucleus pulposus cells 20 μM To evaluate the effect of iFSP1 on nucleus pulposus cell apoptosis, results showed that 20 μM iFSP1 significantly induced cell death. PMC11565395

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Ovarian cancer xenograft model Intraperitoneal injection 2 mg/kg/d Once daily for 14 days Evaluate the anti-tumor effect of iFSP1 combined with olaparib in ovarian cancer xenograft models PMC11043371
BALB/c mice 4T1 breast cancer model Intravenous injection 100 μM Single injection, lasting 14 days Evaluate the anti-tumor and anti-metastasis effects of TiF NPs in vivo. Results showed that TiF NPs combined with ultrasound irradiation significantly inhibited tumor growth and lung metastasis and activated anti-tumor immune responses. PMC11732120
C57BL/6N mice HDTVi-induced HCC model Intraperitoneal injection 10 mg/kg Daily for 4 weeks IFSP1 significantly suppressed HCC tumor growth and increased intratumoral immune cell infiltration (DCs, macrophages, CD4+ and CD8+ T cells) PMC10230009
Sprague-Dawley rats Coccygeal vertebral needle puncture model In situ injection 10 μM To evaluate the effect of iFSP1 on intervertebral disc degeneration, results showed that iFSP1 significantly ameliorated disc degeneration. PMC11565395
C57BL/6J mice Sepsis-associated encephalopathy model Intraperitoneal injection 500 mg/kg Twice a week until the end of the experiment To investigate the effect of iFSP1 on ferroptosis in the hippocampus of septic mice, results showed that iFSP1 combined with RSL3 further reversed the inhibitory effect of APAP on ferroptosis. PMC10454284

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.46mL

3.09mL

1.55mL

30.93mL

6.19mL

3.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories